Literature DB >> 35260802

The schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain.

Robert G Mealer1,2,3,4, Sarah E Williams5,6, Maxence Noel6, Bo Yang7, Alexandria K D'Souza7, Toru Nakata8,9,10, Daniel B Graham8,9,10, Elizabeth A Creasey8,9,10, Murat Cetinbas9, Ruslan I Sadreyev9, Edward M Scolnick5,11, Christina M Woo7, Jordan W Smoller5,12,11, Ramnik J Xavier8,9,10, Richard D Cummings6.   

Abstract

A missense mutation (A391T) in SLC39A8 is strongly associated with schizophrenia in genomic studies, though the molecular connection to the brain is unknown. Human carriers of A391T have reduced serum manganese, altered plasma glycosylation, and brain MRI changes consistent with altered metal transport. Here, using a knock-in mouse model homozygous for A391T, we show that the schizophrenia-associated variant changes protein glycosylation in the brain. Glycosylation of Asn residues in glycoproteins (N-glycosylation) was most significantly impaired, with effects differing between regions. RNAseq analysis showed negligible regional variation, consistent with changes in the activity of glycosylation enzymes rather than gene expression. Finally, nearly one-third of detected glycoproteins were differentially N-glycosylated in the cortex, including members of several pathways previously implicated in schizophrenia, such as cell adhesion molecules and neurotransmitter receptors that are expressed across all cell types. These findings provide a mechanistic link between a risk allele and potentially reversible biochemical changes in the brain, furthering our molecular understanding of the pathophysiology of schizophrenia and a novel opportunity for therapeutic development.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35260802      PMCID: PMC9106890          DOI: 10.1038/s41380-022-01490-1

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  54 in total

1.  Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency.

Authors:  S J Enna; J P Bennett; D R Burt; I Creese; S H Snyder
Journal:  Nature       Date:  1976-09-23       Impact factor: 49.962

Review 2.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

3.  A polygenic theory of schizophrenia.

Authors:  I I Gottesman; J Shields
Journal:  Proc Natl Acad Sci U S A       Date:  1967-07       Impact factor: 11.205

Review 4.  Schizophrenia.

Authors:  Stephen R Marder; Tyrone D Cannon
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245

5.  The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.

Authors:  J M van Rossum
Journal:  Arch Int Pharmacodyn Ther       Date:  1966-04

Review 6.  Defining the Genetic, Genomic, Cellular, and Diagnostic Architectures of Psychiatric Disorders.

Authors:  Patrick F Sullivan; Daniel H Geschwind
Journal:  Cell       Date:  2019-03-21       Impact factor: 41.582

Review 7.  Recent Advances in the Genetics of Schizophrenia.

Authors:  Dimitrios Avramopoulos
Journal:  Mol Neuropsychiatry       Date:  2018-05-30

Review 8.  Psychiatric genetics and the structure of psychopathology.

Authors:  Jordan W Smoller; Ole A Andreassen; Howard J Edenberg; Stephen V Faraone; Stephen J Glatt; Kenneth S Kendler
Journal:  Mol Psychiatry       Date:  2018-01-09       Impact factor: 15.992

Review 9.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

10.  Schizophrenia risk from complex variation of complement component 4.

Authors:  Aswin Sekar; Allison R Bialas; Heather de Rivera; Avery Davis; Timothy R Hammond; Nolan Kamitaki; Katherine Tooley; Jessy Presumey; Matthew Baum; Vanessa Van Doren; Giulio Genovese; Samuel A Rose; Robert E Handsaker; Mark J Daly; Michael C Carroll; Beth Stevens; Steven A McCarroll
Journal:  Nature       Date:  2016-01-27       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.